Skip Navigation



JAC Advance Access published online on October 3, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl398
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/6/1264    most recent
dkl398v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Drudy, D.
Right arrow Articles by Fanning, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drudy, D.
Right arrow Articles by Fanning, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received June 16, 2006
Revised August 22, 2006
Accepted September 11, 2006

Brief report

High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile

Denise Drudy 1 *, Teresa Quinn 1, Rebecca O'Mahony 1, Lorraine Kyne 2, Peadar Ó'Gaora 3, and Séamus Fanning 1

1 Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland
2 Department of Medicine for the Older Person, Mater Misericordiae University Hospital, Dublin 7, Ireland
3 UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland

* To whom correspondence should be addressed.
Denise Drudy, E-mail: denise.drudy{at}ucd.ie


  Abstract

Objectives: To determine the mechanism of high-level resistance to fluoroquinolone antimicrobials in toxin-A-negative, toxin-B-positive (A-B+) Clostridium difficile isolates.

Methods: Following culture 16-23S PCR ribotyping was used to determine genomic relationships between A-B+ C. difficile isolates. Antimicrobial susceptibilities were determined using Etests in the presence and absence of the efflux pump inhibitors reserpine (20 µg/mL), L-phenylalanine-L-arginine-{beta}-naphthylamide (PA{beta}N; 20 µg/mL) and verapamil (100 µg/mL). Genomic regions including the quinolone-resistance-determining-region (QRDR) of gyrA and gyrB were amplified and characterized.

Results: PCR ribotyping profiles identified one major cluster of A-B+ C. difficile, universally resistant to the fluoroquinolones tested (ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin; MICs > 32 mg/L). All isolates with high-level resistance had a transversion mutation (A->T) resulting in the amino acid substitution Asp-426->Val in gyrB. Non-clonal isolates were susceptible to moxifloxacin and gatifloxacin (MICs 0.3 and 0.4 mg/L, respectively) with reduced susceptibility to levofloxacin (MIC 3 mg/L) consistent with the wild-type genotype. The MICs for resistant isolates were not significantly affected by the addition of any of the efflux pump inhibitors. No amino acid substitutions were identified in the QRDR of gyrA.

Conclusions: High-level resistance to fluoroquinolones in A-B+ C. difficile is associated with a novel transversion mutation in gyrB. The emergence of universal resistance in different C. difficile strain types may be a factor promoting outbreaks in hospitals.

Keywords: fluoroquinolone resistance; A-B+ C. difficile; transversion mutation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
P. Spigaglia, F. Barbanti, T. Louie, F. Barbut, and P. Mastrantonio
Molecular Analysis of the gyrA and gyrB Quinolone Resistance-Determining Regions of Fluoroquinolone-Resistant Clostridium difficile Mutants Selected In Vitro
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2463 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. A. Critchley, L. S. Green, C. L. Young, J. M. Bullard, R. J. Evans, M. Price, T. C. Jarvis, J. W. Guiles, N. Janjic, and U. A. Ochsner
Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
J. Antimicrob. Chemother., May 1, 2009; 63(5): 954 - 963.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox
Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
A. Wright, D. Drudy, L. Kyne, K. Brown, and N. F. Fairweather
Immunoreactive cell wall proteins of Clostridium difficile identified by human sera
J. Med. Microbiol., June 1, 2008; 57(6): 750 - 756.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
P. Spigaglia, F. Barbanti, P. Mastrantonio, J. S. Brazier, F. Barbut, M. Delmee, E. Kuijper, I. R. Poxton, and on behalf of the European Study Group on Clostridi
Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe
J. Med. Microbiol., June 1, 2008; 57(6): 784 - 789.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
H. Kim, T. V. Riley, M. Kim, C. K. Kim, D. Yong, K. Lee, Y. Chong, and J.-W. Park
Increasing Prevalence of Toxin A-Negative, Toxin B-Positive Isolates of Clostridium difficile in Korea: Impact on Laboratory Diagnosis
J. Clin. Microbiol., March 1, 2008; 46(3): 1116 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. J Mehlhorn and D. A Brown
Safety Concerns with Fluoroquinolones
Ann. Pharmacother., November 1, 2007; 41(11): 1859 - 1866.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.